Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

12.08
+0.15001.26%
Post-market: 12.080.00000.00%16:38 EDT
Volume:1.37M
Turnover:16.57M
Market Cap:1.82B
PE:-2.70
High:12.27
Open:11.90
Low:11.75
Close:11.93
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:0.61
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:148.67
PE(LYR):-1.76

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 31

How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy

Simply Wall St.
·
Jul 28

Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

MT Newswires Live
·
Jul 27

Biohaven, Yale Win USD 4 Million Jury Verdict over MODA Trade Secret Theft

Reuters
·
Jul 27

Biohaven reports new data on BHV-1530

TIPRANKS
·
Jul 20

Biohaven enters into clinical supply agreement with Regeneron

TIPRANKS
·
Jul 20

Biohaven Signs Regeneron Supply Deal to Test Bhv-1530 with Libtayo

Reuters
·
Jul 20

Biohaven to Present New Clinical Data at Esmo Congress on Bhv-1530, a Novel Fgfr3-directed ADC with a Proprietary Topoisomerase I (topoix) Payload

THOMSON REUTERS
·
Jul 20

Biohaven Files Form 3 for Chief Legal Officer Warren Karl Volles

Reuters
·
Jul 18

Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer

MT Newswires Live
·
Jul 10

Biohaven’s Bruce Car retires as chief scientific officer

TIPRANKS
·
Jul 10

Biohaven Promotes David Pirman to EVP, Head of Discovery

Reuters
·
Jul 10

Press Release: Biohaven Announces Scientific Leadership Transitions

Dow Jones
·
Jul 10

Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)

TIPRANKS
·
Jul 01

Biohaven announces completion of enrollment in RISE3 trial

TIPRANKS
·
Jun 30

Biohaven - Completes Enrollment in Rise3 Pivotal Phase 2/3 Focal Epilepsy Study with Opakalim

THOMSON REUTERS
·
Jun 30

Biohaven - Top-line Results from Rise3 Study Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 30

Biohaven Completes Enrollment in RISE3 Pivotal Opakalim Focal Epilepsy Trial, Data Due 2H 2026

Reuters
·
Jun 30

Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at Bofa

Dow Jones
·
Jun 30

Biohaven falls -9.8%

TIPRANKS
·
Jun 29